Access to palivizumab among children at high risk of respiratory syncytial virus complications in English hospitals.

In England, palivizumab is not prescribed to the majority of children who are eligible to receive it. Doctors managing these infants may be unfamiliar with the eligibility criteria or constrained by other considerations, such as cost.